Mind Medicine (MindMed) Inc. / Definium Therapeutics — Cyborg Score 7/10
Strong
Biopharmaceutical / Psychedelic-Inspired Therapeutics / Clinical-Stage Drug Development
Strategic Profile
The company's mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. 2026 is positioned as a transformational year with accelerated Phase 3 data readout from the Emerge MDD trial expected in mid-2026 and plans to initiate Ascend, a second Phase 3 MDD study.
Cyborg Score Rationale
The company has secured $209.1M in cash and equivalents plus $242.8M from a recent offering, with guidance to fund operations into 2028. Phase 2b MM120 GAD results showed 65% response and 48% remission rates at Week 12. However, the company remains pre-commercial with clinical execution risk ahead of 2026 readouts.
Top Insights
Recently rebranded to Definium Therapeutics (January 2026) to better reflect evolution as late-stage psychiatry-focused developer
Lead candidate MM120 ODT has four Phase 3 trials underway: two in GAD (Voyage, Panorama) and two in MDD (Emerge, Ascend)
Strong balance sheet with $451.9M in total liquidity (cash + recent offering) and runway through 2028
Pipeline expansion underway with MM402 Phase 2a study in Autism Spectrum Disorder planned for Q4 2025
Named Competitors
COMP360 (psilocybin) — Phase 3 development for treatment-resistant depression
CERC-501 (serotonin receptor modulator) — Depression and anxiety targeting alternative psychedelic mechanisms
Traditional psychiatric medicines — Established antidepressants and anti-anxiety medications
Recent Developments
(January 2026) Company rebranded from Mind Medicine to Definium Therapeutics; ticker changed from MNMD to DFTX on January 13
(November 2025) Q3 2025 results released; Phase 2b GAD study published in JAMA showing 65% response and 48% remission
(October 2025) Completed underwritten public offering with net proceeds of $242.8 million to fund R&D and clinical programs
Open the full interactive Mind Medicine (MindMed) Inc. / Definium Therapeutics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.